Imperial College London
Portrait Picture

Dr. David James PINATO

Faculty of Medicine, Department of Surgery & Cancer

Clinical Reader in Medical Oncology
 
 
 
//

Contact

 

+44 (0)20 7594 2799david.pinato Website

 
 
//

Location

 

ICTEM buildingHammersmith Campus

//

Summary

 

Publications

Publication Type
Year
to

505 results found

Banna GL, Cantale O, Muthuramalingam S, Cave J, Comins C, Cortellini A, Addeo A, Signori A, McKenzie H, Escriu C, Barone G, Chan S, Hicks A, Bainbridge H, Pinato DJ, Ottensmeier C, Gomes Fet al., 2022, Efficacy outcomes and prognostic factors from real-world patients with advanced non-small-cell lung cancer treated with first-line chemoimmunotherapy: The Spinnaker retrospective study, INTERNATIONAL IMMUNOPHARMACOLOGY, Vol: 110, ISSN: 1567-5769

Journal article

Auclin E, Benitez-Montanez J, Gorria T, Garcia-Campelo R, Dempsey N, Pinato DJ, Reyes R, Albarran V, Dall'ollio F, Soldato D, Hendriks L, Aboubakar F, Tonneau M, Lopez-Castro R, Nadal E, Katsandjian S, Blanc-Durand F, Fabre E, Castro N, Arasanz H, Muanza T, Rochand A, Besse B, Routy B, Mezquita Let al., 2022, Second Line Treatment Outcomes After Progression on Immunotherapy Plus Chemotherapy (IO-CT) In Advanced Non-small Cell Lung Cancer (aNSCLC), Publisher: ELSEVIER SCIENCE INC, Pages: S22-S22, ISSN: 1556-0864

Conference paper

Jones RH, Pinato DJ, Joshua A, Forster MD, Morton C, Aboud K, Liu JJ, Fulgenzi C, Kefas J, Edmondson S, Main NJ, Paull JRA, Fairley JK, Spicer Jet al., 2022, Efficacy and safety of dendrimer-enhanced (DEP) cabazitaxel (CTX-SPL9111) in men with metastatic castration-resistant prostate cancer (mCRPC) in a phase I/II trial, Annual Meeting of the European-Society-for-Medical-Oncology (ESMO), Publisher: ELSEVIER, Pages: S1186-S1187, ISSN: 0923-7534

Conference paper

Pinato DJ, Aguilar-Company J, Bertuzzi A, Hanbury GH, Bower MD, Salazar R, Lambertini M, Pedrazzoli P, Lee AJX, Sinclair A, Townsend S, Salarich AP, Sita-Lumsden AR, Mukherjee U, Diamantis N, Sharkey R, Gaidano G, Gennari A, Tabernero J, Cortellini Aet al., 2022, SARS-CoV-2 Omicron (B.1.1.529) variant infection leads to high morbidity and mortality in unvaccinated patients with cancer, Annual Meeting of the European-Society-for-Medical-Oncology (ESMO), Publisher: ELSEVIER, Pages: S773-S774, ISSN: 0923-7534

Conference paper

Cortellini A, Aguilar-Company J, Salazar R, Bower M, Sita-Lumsden A, Plaja A, Lee AJX, Bertuzzi A, Tondini C, Diamantis N, Martinez-Vila C, Prat A, Apthorp E, Gennari A, Pinato DJet al., 2022, Natural immunity to SARS-CoV-2 and breakthrough infections in vaccinated and unvaccinated patients with cancer, British Journal of Cancer, Vol: 127, Pages: 1787-1792, ISSN: 0007-0920

BackgroundConsolidated evidence suggests spontaneous immunity from SARS-CoV-2 is not durable, leading to the risk of reinfection, especially in the context of newly emerging viral strains. In patients with cancer who survive COVID-19 prevalence and severity of SARS-CoV-2 reinfections are unknown.MethodsWe aimed to document natural history and outcome from SARS-CoV-2 reinfection in patients recruited to OnCovid (NCT04393974), an active European registry enrolling consecutive patients with a history of solid or haematologic malignancy diagnosed with COVID-19.ResultsAs of December 2021, out of 3108 eligible participants, 1806 COVID-19 survivors were subsequently followed at participating institutions. Among them, 34 reinfections (1.9%) were reported after a median time of 152 days (range: 40–620) from the first COVID-19 diagnosis, and with a median observation period from the second infection of 115 days (95% CI: 27–196). Most of the first infections were diagnosed in 2020 (27, 79.4%), while most of reinfections in 2021 (25, 73.5%). Haematological malignancies were the most frequent primary tumour (12, 35%). Compared to first infections, second infections had lower prevalence of COVID-19 symptoms (52.9% vs 91.2%, P = 0.0008) and required less COVID-19-specific therapy (11.8% vs 50%, P = 0.0013). Overall, 11 patients (32.4%) and 3 (8.8%) were fully and partially vaccinated against SARS-CoV-2 before the second infection, respectively. The 14-day case fatality rate was 11.8%, with four death events, none of which among fully vaccinated patients.ConclusionThis study shows that reinfections in COVID-19 survivors with cancer are possible and more common in patients with haematological malignancies. Reinfections carry a 11% risk of mortality, which rises to 15% among unvaccinated patients, highlighting the importance of universal vaccination of patients with cancer.

Journal article

Cortellini A, Ricciuti B, Borghaei H, Naqash AR, D'Alessio A, Fulgenzi CAM, Addeo A, Banna GL, Pinato DJet al., 2022, Differential prognostic effect of systemic inflammation in patients with non-small cell lung cancer treated with immunotherapy or chemotherapy: A post hoc analysis of the phase 3 OAK trial, CANCER, Vol: 128, Pages: 3067-3079, ISSN: 0008-543X

Journal article

Fulgenzi CAM, D'Alessio A, Talbot T, Gennari A, Openshaw MR, Demirtas CO, Cortellini A, Pinato DJet al., 2022, New Frontiers in the Medical Therapy of Hepatocellular Carcinoma, CHEMOTHERAPY, Vol: 67, Pages: 164-172, ISSN: 0009-3157

Journal article

Munoz-Martinez S, Sapena V, Forner A, Bruix J, Sanduzzi-Zamparelli M, Rios J, Bouattour M, El-Kassas M, Leal CRG, Mocan T, Nault J-C, Alves RCP, Reeves HL, da Fonseca L, Garcia-Juarez I, Pinato DJ, Varela M, Alqahtani SA, Alvares-da-Silva MR, Bandi JC, Rimassa L, Lozano M, Gonzalez Santiago JM, Tacke F, Sala M, Anders M, Lachenmayer A, Pinero F, Franca A, Guarino M, Elvevi A, Cabibbo G, Peck-Radosavljevic M, Rojas A, Vergara M, Braconi C, Pascual S, Perello C, Mello V, Rodriguez-Lope C, Acevedo J, Villani R, Hollande C, Vilgrain V, Tawheed A, Theodoro CF, Sparchez Z, Blaise L, Viera-Alves DE, Watson R, Carrilho FJ, Moctezuma-Velazquez C, D'Alessio A, Iavarone M, Reig Met al., 2022, Outcome of liver cancer patients with SARS-CoV-2 infection: An International, Multicentre, Cohort Study, LIVER INTERNATIONAL, Vol: 42, Pages: 1891-1901, ISSN: 1478-3223

Journal article

Barsch M, Salie H, Schlaak AE, Zhang Z, Hess M, Mayer LS, Tauber C, Otto-Mora P, Ohtani T, Nilsson T, Wischer L, Winkler F, Manne S, Rech A, Schmitt-Graeff A, Bronsert P, Hofmann M, Neumann-Haefelin C, Boettler T, Fichtner-Feigl S, van Boemmel F, Berg T, Rimassa L, Di Tommaso L, Saeed A, D'Alessio A, Pinato DJ, Bettinger D, Binder H, Wherry EJ, Schultheiss M, Thimme R, Bengsch Bet al., 2022, T-cell exhaustion and residency dynamics inform clinical outcomes in hepatocellular carcinoma, JOURNAL OF HEPATOLOGY, Vol: 77, Pages: 397-409, ISSN: 0168-8278

Journal article

Fulgenzi CAM, D'Alessio A, Ogunbiyi O, Demirtas CO, Gennari A, Cortellini A, Sharma R, Pinato DJet al., 2022, Novel immunotherapy combinations in clinical trials for hepatocellular carcinoma: will they shape the future treatment landscape?, EXPERT OPINION ON INVESTIGATIONAL DRUGS, Vol: 31, Pages: 681-691, ISSN: 1354-3784

Journal article

Johnson PJ, Pinato DJ, Kalyuzhnyy A, Toyoda Het al., 2022, Breaking the Child-Pugh Dogma in Hepatocellular Carcinoma comment, JOURNAL OF CLINICAL ONCOLOGY, Vol: 40, Pages: 2078-+, ISSN: 0732-183X

Journal article

D'Alessio A, Pai M, Spalding D, Rajagopal P, Talbot T, Goldin R, Fulgenzi CAM, Ward C, Yip V, Dhillon T, Slater S, Sodergren M, Tait P, Habib N, Thomas R, Cortellini A, Sharma R, Pinato DJet al., 2022, PRIME-HCC: phase Ib study of neoadjuvant ipilimumab and nivolumab prior to liver resection for hepatocellular carcinoma, International Liver Congress, Publisher: ELSEVIER, Pages: S108-S109, ISSN: 0168-8278

Conference paper

D'Alessio A, Weinmann A, Galle P, Gaillard V, Fulgenzi CAM, Bettinger D, Bengsch B, Vogel A, Balcar L, Scheiner B, Amara S, Muzaffar M, Naqash AR, Personeni N, Pressiani T, Sharma R, Pinter M, Cortellini A, Rimassa L, Pinato DJet al., 2022, Preliminary evidence of safety and tolerability of atezolizumab plus bevacizumab in patients with hepatocellular carcinoma and Child-Pugh A and B cirrhosis: a real-world study, JOURNAL OF HEPATOLOGY, Vol: 77, Pages: S376-S376, ISSN: 0168-8278

Journal article

Sharma R, Pillai A, Marron TU, Fessas P, Saeed A, Jun T, Dharmapuri S, Szafron D, Naqash AR, Gampa A, Wang Y, Khan U, Muzaffar M, Lee C-J, Lee P-C, Bulumulle A, Paul S, Bettinger D, Hildebrand H, Yehia M, Pressiani T, Kaseb A, Huang Y-H, Ang C, Kudo M, Nishida N, Personeni N, Rimassa L, Pinato DJet al., 2022, Patterns and outcomes of subsequent therapy after immune checkpoint inhibitor discontinuation in HCC, Hepatology Communications, Vol: 6, Pages: 1776-1785, ISSN: 2471-254X

The availability of immune checkpoint inhibitors (ICIs) for the management of advanced hepatocellular cancer (HCC) has changed the treatment paradigm. There are emerging questions regarding the efficacy of subsequent anticancer therapies. The primary aim of this retrospective, multicenter study was to examine the types of anticancer treatment received after ICIs and to assess the impact on post-ICI survival. We established an international consortium of 11 tertiary-care referral centers located in the USA (n = 249), Europe (n = 74), and Asia (n = 97), and described patterns of care following ICI therapy. The impact of subsequent therapy on overall survival (OS) was estimated using the Kaplan–Meier method and presented with a 95% confidence interval (CI). A total of 420 patients were treated with ICIs for advanced HCC after one line of systemic therapy (n = 371, 88.8%): 31 (8.8%) had died, 152 (36.2%) received best supportive care (BSC) following ICIs, and 163 patients (38.8%) received subsequent anticancer therapy. Tyrosine kinase inhibitors (TKIs, n = 132, 80.9%), in particular sorafenib (n = 49, 30.0%), were the most common post-ICI therapy followed by external beam radiotherapy (n = 28, 17.2%), further immunotherapy (n = 21, 12.9%), locoregional therapy (n = 23, 14.1%), chemotherapy (n = 9, 5.5%), and surgery (n = 6, 3.6%). Receipt of post-ICI therapy was associated with longer median OS compared with those who had received BSC (12.1 vs. 3.3 months; hazard ratio [HR]: 0.4 (95% CI: 2.7–5.0). No difference in OS was noted in those patients who received TKI before ICIs compared with those who received ICIs followed by TKI. Conclusion: Post-ICI therapy is associated with OS in excess of 12 months, suggesting a role for therapeutic sequencing. OS from TKI therapy was similar to that reported in registration studies, suggesting preserved efficacy following ICIs.

Journal article

Fulgenzi C, Muhammed A, Dharmapuri S, Pinter M, Balcar L, Scheiner B, Marron TU, Jun T, Saeed A, Hildebrand H, Muzaffar M, Navaid M, Naqash AR, Gampa A, Ozbek U, Lin J-Y, Perone Y, Vincenzi B, Siletta M, Pillai A, Wang Y, Khan U, Huang Y-H, Bettinger D, Abugabal Y, Kaseb A, Pressiani T, Personeni N, Rimassa L, Nishida N, Di Tommaso L, Kudo M, Vogel A, Mauri F, Cortellini A, Sharma R, D'Alessio A, Ang C, Pinato DJet al., 2022, The systemic inflammatory response identifies patients with adverse clinical outcome from immunotherapy in hepatocellular carcinoma, Publisher: ELSEVIER, Pages: S372-S373, ISSN: 0168-8278

Conference paper

Pinato DJ, Aguilar-Company J, Ferrante D, Hanbury G, Bower M, Salazar R, Mirallas O, Sureda A, Plaja A, Cucurull M, Mesia R, Townsend S, Jackson A, Dalla Pria A, Newsom-Davis T, Handford J, Sita-Lumsden A, Apthorp E, Vincenzi B, Bertuzzi A, Brunet J, Lambertini M, Maluquer C, Pedrazzoli P, Biello F, Sinclair A, Bawany S, Khalique S, Rossi S, Rogers L, Murphy C, Belessiotis K, Carmona-Garcia MC, Sharkey R, Garcia-Illescas D, Rizzo G, Perachino M, Saoudi-Gonzalez N, Doonga K, Fox L, Roldan E, Gaidano G, Ruiz-Camps I, Bruna R, Patriarca A, Martinez-Vila C, Cantini L, Zambelli A, Giusti R, Mazzoni F, Caliman E, Santoro A, Grosso F, Parisi A, Queirolo P, Aujayeb A, Rimassa L, Prat A, Tucci M, Libertini M, Grisanti S, Mukherjee U, Diamantis N, Fusco V, Generali D, Provenzano S, Gennari A, Tabernero J, Cortellini Aet al., 2022, Outcomes of the SARS-CoV-2 omicron (B.1.1.529) variant outbreak among vaccinated and unvaccinated patients with cancer in Europe: results from the retrospective, multicentre, OnCovid registry study, The Lancet Oncology, Vol: 23, Pages: 865-875, ISSN: 1213-9432

BackgroundThe omicron (B.1.1.529) variant of SARS-CoV-2 is highly transmissible and escapes vaccine-induced immunity. We aimed to describe outcomes due to COVID-19 during the omicron outbreak compared with the prevaccination period and alpha (B.1.1.7) and delta (B.1.617.2) waves in patients with cancer in Europe.MethodsIn this retrospective analysis of the multicentre OnCovid Registry study, we recruited patients aged 18 years or older with laboratory-confirmed diagnosis of SARS-CoV-2, who had a history of solid or haematological malignancy that was either active or in remission. Patient were recruited from 37 oncology centres from UK, Italy, Spain, France, Belgium, and Germany. Participants were followed up from COVID-19 diagnosis until death or loss to follow-up, while being treated as per standard of care. For this analysis, we excluded data from centres that did not actively enter new data after March 1, 2021 (in France, Germany, and Belgium). We compared measures of COVID-19 morbidity, which were complications from COVID-19, hospitalisation due to COVID-19, and requirement of supplemental oxygen and COVID-19-specific therapies, and COVID-19 mortality across three time periods designated as the prevaccination (Feb 27 to Nov 30, 2020), alpha-delta (Dec 1, 2020, to Dec 14, 2021), and omicron (Dec 15, 2021, to Jan 31, 2022) phases. We assessed all-cause case-fatality rates at 14 days and 28 days after diagnosis of COVID-19 overall and in unvaccinated and fully vaccinated patients and in those who received a booster dose, after adjusting for country of origin, sex, age, comorbidities, tumour type, stage, and status, and receipt of systemic anti-cancer therapy. This study is registered with ClinicalTrials.gov, NCT04393974, and is ongoing.FindingsAs of Feb 4, 2022 (database lock), the registry included 3820 patients who had been diagnosed with COVID-19 between Feb 27, 2020, and Jan 31, 2022. 3473 patients were eligible for inclusion (1640 [47·4%] were women and

Journal article

Pinato DJ, Ferrante D, Aguilar-Company J, Bower M, Salazar R, Mirallas O, Sureda A, Bertuzzi A, Brunet J, Lambertini M, Maluquer C, Pedrazzoli P, Biello F, Lee AJX, Sng CCT, Linan R, Rossi S, Carmen Carmona-Garcia M, Sharkey R, Eremiev S, Rizzo G, Bain HDC, Yu T, Cruz CA, Perachino M, Saoudi-Gonzalez N, Fort-Culillas R, Doonga K, Fox L, Roldan E, Zoratto F, Gaidano G, Ruiz-Camps I, Bruna R, Patriarca A, Shawe-Taylor M, Fusco V, Martinez-Vila C, Berardi R, Filetti M, Mazzoni F, Santoro A, Delfanti S, Parisi A, Queirolo P, Aujayeb A, Rimassa L, Prat A, Tabernero J, Gennari A, Cortellini Aet al., 2022, Vaccination against SARS-CoV-2 protects from morbidity, mortality and sequelae from COVID19 in patients with cancer, European Journal of Cancer, Vol: 171, Pages: 64-74, ISSN: 0959-8049

BackgroundAlthough SARS-CoV-2 vaccines immunogenicity in patients with cancer has been investigated, whether they can significantly improve the severity of COVID-19 in this specific population is undefined.MethodsCapitalizing on OnCovid (NCT04393974) registry data we reported COVID-19 mortality and proxies of COVID-19 morbidity, including post-COVID-19 outcomes, according to the vaccination status of the included patients.Results2090 eligible patients diagnosed with COVID-19 between 02/2020 and 11/2021 were included, of whom 1930 (92.3%) unvaccinated, 91 (4.4%) fully vaccinated and 69 (3.3%) partially vaccinated. With the exception of a higher prevalence of patients from the UK (p = 0.0003) and receiving systemic anticancer therapy at COVID-19 diagnosis (p = 0.0082) among fully vaccinated patients, no demographics/oncological features were associated with vaccination status. The 14-days case fatality rate (CFR) (5.5% vs 20.7%, p = 0.0004) and the 28-days CFR (13.2% vs 27.4%, p = 0.0028) demonstrated a significant improvement for fully vaccinated patients in comparison with unvaccinated patients. The receipt of prior full vaccination was also associated with reduced symptomatic COVID-19 (79.1% vs 88.5%, p = 0.0070), need of COVID-19 oriented therapy (34.9% vs 63.2%, p < 0.0001), complications from COVID-19 (28.6% vs 39.4%, p = 0.0379), hospitalizations due to COVID-19 (42.2% vs 52.5%, p = 0.0007) and oxygen therapy requirement (35.7% vs 52%, p = 0.0036). Following Inverse Probability Treatment Weighting (IPTW) procedure no statistically significant difference according to the vaccination status was confirmed; however, all COVID-19 related outcomes were concordantly in favour of full vaccination. Among the 1228 (58.8%) patients who underwent a formal reassessment at participating centres after COVID-19 resolution, fully vaccinated patients experienced less sequelae than unvaccinated patients (6.7% vs 17.2%, p = 0.0320).ConclusionsThis analysis provides initial evid

Journal article

Cortellini A, Ricciuti B, Borghaei H, Naqash AR, D'Alessio A, Fulgenzi CAM, Addeo A, Banna GLL, Pinato DJJet al., 2022, Differential prognostic effect of systemic inflammation in patients with NSCLC treated with immunotherapy or chemotherapy: A post hoc analysis of the phase III OAK trial., Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Publisher: LIPPINCOTT WILLIAMS & WILKINS, ISSN: 0732-183X

Conference paper

Warner JL, Pinato DJJ, Mishra S, Saliby RM, Hwang C, Gulati S, Mckay RR, Labaki C, Griffiths EA, Jani C, Yu PP, Portuguese AJ, Puc M, Egan P, Shah S, Kasi A, Berg SA, Flora DB, Accordino MK, Shah DPet al., 2022, Post-acute sequelae of SARS-CoV-2 infection in patients with cancer., Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Publisher: LIPPINCOTT WILLIAMS & WILKINS, Pages: E18746-E18746, ISSN: 0732-183X

Conference paper

Pinato DJJ, Li X, Mishra-Kalyani PS, D'Alessio A, Fulgenzi CAM, Wei G, Schneider JA, Rivera D, Pazdur R, Theoret MR, Casak SJ, Lemery S, Fashoyin I, Cortellini A, Pelosof LCet al., 2022, Antibiotic therapy and association with oncological outcomes from targeted and immune-based therapy in hepatocellular carcinoma (HCC)., Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Publisher: LIPPINCOTT WILLIAMS & WILKINS, ISSN: 0732-183X

Conference paper

Fulgenzi CAM, D'Alessio A, Scotti L, Airoldi C, Coskun D, Gennari A, Cortellini A, Pinato DJJet al., 2022, Comparative efficacy of novel combination immunotherapy strategies for unresectable hepatocellular carcinoma (HCC): A network metanalysis of landmark phase III trials., Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Publisher: LIPPINCOTT WILLIAMS & WILKINS, ISSN: 0732-183X

Conference paper

Rakaee M, Adib E, Ricciuti B, Sholl LM, Shi W, Alessi JVM, Cortellini A, Fulgenzi CAM, Pinato DJJ, Hashemi SM, Bahce I, Houda I, Jamaly S, Andersen S, Donnem T, Awad MM, Kwiatkowski DJet al., 2022, Artificial intelligence in digital pathology approach identifies the predictive impact of tertiary lymphoid structures with immune-checkpoints therapy in NSCLC., Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Publisher: LIPPINCOTT WILLIAMS & WILKINS, ISSN: 0732-183X

Conference paper

Pinato DJJ, Aguilar-Company J, Ferrante D, Hanbury GH, Bower M, Salazar R, Lambertini M, Pedrazzoli P, Lee AJX, Sinclair A, Townsed S, Plaja A, Tucci M, Sita-Lumsden A, Mukherjee U, Mazzoni F, Aujayeb A, Gennari A, Tabernero J, Cortellini Aet al., 2022, Clinical effectiveness of SARS-CoV-2 vaccines and booster doses in patients with cancer: An analysis from the European OnCovid registry., Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Publisher: LIPPINCOTT WILLIAMS & WILKINS, Pages: E18725-E18725, ISSN: 0732-183X

Conference paper

D'Alessio A, Pai M, Spalding D, Rajagopal P, Talbot T, Goldin R, Fulgenzi CAM, Ward C, Yip V, Slater S, Sodergren M, Tait P, Habib NA, Thomas R, Cortellini A, Sharma R, Pinato DJJet al., 2022, Preliminary results from a phase Ib study of neoadjuvant ipilimumab plus nivolumab prior to liver resection for hepatocellular carcinoma: The PRIME-HCC trial., Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Publisher: LIPPINCOTT WILLIAMS & WILKINS, ISSN: 0732-183X

Conference paper

Fulgenzi CAM, Cortellini A, D'Alessio A, Thomas R, Tait P, Ross PJ, Young A-M, Talbot T, Goldin R, Ward C, Bengsch B, Sharma R, Pinato DJJet al., 2022, A phase Ib study of pembrolizumab following trans-arterial chemoembolization (TACE) in hepatocellular carcinoma (HCC): PETAL., Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Publisher: LIPPINCOTT WILLIAMS & WILKINS, Pages: E16195-E16195, ISSN: 0732-183X

Conference paper

Dharmapuri S, Ozbek U, Saeed A, Muzaffar M, Amara S, Personeni N, Pressiani T, Nishida N, Paul S, Bettinger D, Khan U, Fessas P, Huang Y-H, Kaseb AO, Pillai A, Rimassa L, Pinato DJJ, Ang Cet al., 2022, Relationship between systemic inflammatory response markers and immune treatment related toxicity (IrAEs) in hepatocellular carcinoma (HCC)., Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Publisher: LIPPINCOTT WILLIAMS & WILKINS, Pages: E16204-E16204, ISSN: 0732-183X

Conference paper

Marinelli B, Kim E, D'Alessio A, Cedillo M, Sinha I, Debnath N, Kudo M, Nishida N, Saeed A, Hildebrand H, Kaseb AO, Abugabal Y, Pillai A, Huang Y-H, Khan U, Muzaffar M, Naqash AR, Patel R, Fischman A, Bishay V, Bettinger D, Sung M, Ang C, Schwartz M, Pinato DJ, Marron Tet al., 2022, Integrated use of PD-1 inhibition and transarterial chemoembolization for hepatocellular carcinoma: evaluation of safety and efficacy in a retrospective, propensity score-matched study, JOURNAL FOR IMMUNOTHERAPY OF CANCER, Vol: 10

Journal article

Cortellini A, Facchinetti F, Derosa L, Pinato DJet al., 2022, Antibiotic Exposure and Immune Checkpoint Inhibitors in Patients With NSCLC: The Backbone Matters, JOURNAL OF THORACIC ONCOLOGY, Vol: 17, Pages: 739-741, ISSN: 1556-0864

Journal article

Cortellini A, Salazar R, Gennari A, Aguilar-Company J, Bower M, Bertuzzi A, Brunet J, Lambertini M, Maluquer C, Pedrazzoli P, Lee AJX, Carmona-Garcia M, Newsom-Davis T, Van Hemelrijck M, Plaja A, Zambelli A, Tondini C, Generali D, Bertulli R, Diamantis N, Mukherjee U, Rizzo G, Yu T, Zoratto F, Bruna R, Sureda A, Martinez-Vila C, Cantini L, Mazzoni F, Grosso F, Parisi A, Saponara M, Prat Aet al., 2022, Original Research Persistence of long-term COVID-19 sequelae in patients with cancer: An analysis from the OnCovid registry, European Journal of Cancer, Vol: 170, Pages: 10-16, ISSN: 0959-8049

IntroductionA significant proportion of patients with cancer who recover from Coronavirus Disease 2019 (COVID-19) may experience COVID-19 sequelae in the early post-infection phase, which negatively affect their continuity of care and oncological outcome. The long-term prevalence and clinical impact of the post-COVID-19 syndrome in patients with cancer are largely unknown.MethodsIn this study, we describe the time course of COVID-19 sequelae in patients with non-advanced cancers enrolled in the OnCovid registry.ResultsOverall, 186 patients were included, with a median observation period of 9.9 months (95%CI:8,8–11.3) post-COVID-19 resolution. After a median interval of 2.3 months post-COVID-19 (interquartile range: 1.4–3.7), 31 patients (16.6%) reported ≥1 sequelae, including respiratory complications (14, 7.6%), fatigue (13, 7.1%), neuro-cognitive sequelae (7, 3.8%). The vast majority of the patients were not vaccinated prior to COVID-19. COVID-19-related sequelae persisted in 9.8% and 8% of patients 6 and 12 months after COVID-19 resolution. Persistence of sequelae at first oncological follow-up was associated with history of complicated COVID-19 (45.2% vs 24.8%, p = 0.0223), irrespective of oncological features at COVID-19 diagnosis.ConclusionThis study confirms for the first time that, in a largely unvaccinated population, post-COVID-19 syndrome can affect a significant proportion of patients with non-advanced cancer who recovered from the acute illness. COVID-19 sequelae may persist up to 12 months in some patients, highlighting the need for dedicated prevention and supportive strategies.

Journal article

Serra C, Cossiga V, Serenari M, Felicani C, Mazzotta E, Pinato DJ, Cescon M, Ercolani G, Cucchetti Aet al., 2022, Safety and efficacy of percutaneous radiofrequency ablation for hepatocellular carcinoma: a textbook outcome analysis, HPB, Vol: 24, Pages: 664-671, ISSN: 1365-182X

Journal article

This data is extracted from the Web of Science and reproduced under a licence from Thomson Reuters. You may not copy or re-distribute this data in whole or in part without the written consent of the Science business of Thomson Reuters.

Request URL: http://wlsprd.imperial.ac.uk:80/respub/WEB-INF/jsp/search-html.jsp Request URI: /respub/WEB-INF/jsp/search-html.jsp Query String: id=00628695&limit=30&person=true&page=7&respub-action=search.html